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The nigrostriatal dopaminergic (NSDA) pathway degenerates in Parkinson’s disease (PD),
which occurs with approximately twice the incidence in men than women. Studies of the
inﬂuence of systemic estrogens in females suggest sex hormones contribute to these dif-
ferences. In this reviewwe analyze the evidence revealing great complexity in the response
of the healthy and injured NSDA system to hormonal inﬂuences, and emphasize the impor-
tance of centrally generated estrogens. At physiological levels, circulating estrogen (in
females) or estrogen precursors (testosterone in males, aromatized to estrogen centrally)
have negligible effects on dopaminergic neuron survival in experimental PD, but canmodify
striatal dopamine levels via actions on the activity or adaptive responses of surviving cells.
However, these effects are sexually dimorphic. In females, estradiol promotes adaptive
responses in the partially injured NSDA pathway, preserving striatal dopamine, whereas
in males gonadal steroids and exogenous estradiol have a negligible or even suppressive
effect, effectively exacerbating dopamine loss. On balance, the different effects of gonadal
factors inmales and females contribute to sex differences in experimental PD. Fundamental
sex differences in brain organization, including the sexually dimorphic networks regulating
NSDA activity are likely to underpin these responses. In contrast, estrogen generated
locally appears to preserve striatal dopamine in both sexes. The available data therefore
highlight the need to understand the biological basis of sex-speciﬁc responses of the NSDA
system to peripheral hormones, so as to realize the potential for sex-speciﬁc, hormone-
based therapies in PD. Furthermore, they suggest that targeting central steroid generation
could be equally effective in preserving striatal dopamine in both sexes. Clariﬁcation of the
relative roles of peripheral and central sex steroid hormones is thus an important challenge
for future studies.
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INTRODUCTION
Sex steroid hormones produced by activation of the hypothalamo-
pituitary–gonadal (HPG) axis have profound effects on brain
development and function. In recent years estrogens have been
a major focus of attention because of their emergent neuropro-
tective, neurotrophic, and psychotropic actions (Fink et al., 1996;
McEwen and Alves, 1999; Gillies et al., 2004; Brann et al., 2007;
Craig and Murphy, 2007). In all mammalian species studied,
including humans, estrogens are considered the steroid hormones
of the female sex due to their roles in regulating ovulation and
reproductive behaviors.Not surprisingly, therefore, the vastmajor-
ity of investigations into the roles of estrogens in the physiology
and pathology of the brain have been conducted in females. These
include studies of neurodegenerative disorders, such as Parkinson’s
disease (PD) and Alzheimer’s disease, as well as schizophrenia and
drug abuse, which show sex differences in their incidence, severity,
Abbreviations: 6-OHDA, 6-hydroxydopamine; MA, methamphetamine; MPTP,
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NSDA pathway, nigrostriatal
dopaminergic pathway; PD, Parkinson’s disease; SNc, substantia nigra pars
compacta.
and/or progression. However, there is a growing realization that
estrogens are also important physiological regulators in males
where they can be synthesized locally in many tissues either de
novo or from steroid precursors, such as circulating testosterone
(Sharpe, 1998; Jones et al., 2006). This includes the brain (DoRego
et al., 2009), where estrogens may act via their classical nuclear
receptors, (ERα and ERβ), which are widely distributed in the
brains of males as well as females, or via rapid membrane effects
(Toran-Allerand, 2005; Balthazart and Ball, 2006; Brann et al.,
2007; Micevych and Dominguez, 2009). This knowledge raises
the possibility that the protective effects of estrogens and estrogen
mimetics may be exploited for the therapy of brain disorders that
affect men as well as women. However, if this potential is to be
realized, we need to understand the relative contributions of sys-
temically and centrally generated steroids to brain function under
both normal and disrupted conditions. This review will focus
on a system well-suited to addressing this issue, the nigrostriatal
dopaminergic (NSDA) pathway that plays a central role in the ﬁne
control of sensorimotor function, and degenerates in PD (Klein
and Schlossmacher, 2007).We shall consider the evidence that this
pathway, whether intact or injured, exhibits sexual dimorphisms
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in its responsiveness to gonadal hormones, as well as innately in its
physiology and pathology in many species. We shall also develop
the view that in contrast to systemic sex steroids of gonadal ori-
gin, which have notable neuroprotective effects in female, but not
male, rodents exposed to experimental PD, centrally generated sex
steroids may be equally beneﬁcial in both sexes.
PARKINSON’S DISEASE: THE CLINICAL PROFILE
ETIOLOGY AND SEX DIFFERENCES
Parkinson’s disease, the second most common neurodegenerative
disorder of aging, affects approximately 1 in 500 people in the
developed world, a ﬁgure set only to increase as the population
ages (Pavon et al., 2010). Clinically, PD is characterized by a core
set of symptoms, namely resting tremor, slowness of movement,
and problems with balance and rigidity, which are commonly
associated with a wide range of secondary symptoms including
depression, anxiety, insomnia, and dementia (Weintraub et al.,
2008). Themajor neuropathological lesion associatedwith the dis-
ease is the loss of dopaminergic input to the caudate nucleus and
putamen (collectively termed the striatum), caused by the degen-
erationof dopaminergic cells in the substantia nigra pars compacta
(SNc). These cells, the origin of the NSDA pathway, play a central
role in the regulation of motor function, and their degeneration
leads to the primary clinical symptoms of PD, although degenera-
tion in other brain areas, including, for example, the noradrenergic
cells of the locus coeruleus and the cholinergic neurons in the
nucleus basalis, contribute to the secondary symptoms associated
with the disease (Braak et al., 2003). Aside from about 3% of
cases that are attributable to a single genetic event, in the major-
ity of cases of PD the underlying cause(s) remain obscure (Klein
and Schlossmacher, 2007). However, the cellular and molecular
processes underlying the degeneration of dopaminergic cells have
been extensively studied, and interactions between mitochondr-
ial failure (Vives-Bauza et al., 2010), oxidative stress (Mattson,
2006), the formation of aggregated α-synuclein positive inclusions
known as Lewy bodies (Auluck et al., 2010) andmicroglial inﬂam-
mation (Halliday and Stevens, 2011) are thought to be responsible
for neuronal death, although there remains some controversy as to
which of these processes has primacy, and which are consequent
upon the others. These ﬁndings support the now widely accepted
theory that PD is a multi-factorial complex disease (probably bet-
ter described as a clinical syndrome), with an etiology comprising
an interaction between multiple genetic factors, the environment,
and aging (Klein and Schlossmacher, 2007).
Being male appears high on the list of factors that contribute
to the development of PD (Klein and Schlossmacher, 2007). Epi-
demiological studies have revealed a clear sex difference in the
incidence (the number of new cases developed in a speciﬁc time-
frame) of PD, with individual studies of male to female ratios
for incidence rates reporting values ranging from 1.37 to 3.7
(Baldereschi et al., 2000; Swerdlow et al., 2001; Van Den Eeden
et al., 2003;Wooten et al., 2004; Shulman and Bhat, 2006; Cantuti-
Castelvetri et al., 2007; Haaxma et al., 2007; Taylor et al., 2007),
with a large meta-analysis study concluding that the relative risk
for men is 1.5 times greater than women (Elbaz et al., 2002). Thus,
whilst approximately 3% of people aged over 65 present with PD,
this ﬁgure breaks down by sex such that 2% of men, but only 1.3%
of women, are affected during their lifetime (Elbaz et al., 2002).
There is some controversy over the presence of sex differences in
the age of onset of clinical PD symptoms, with some studies indi-
cating that men present approximately 2 years earlier than women
(Haaxma et al., 2007; Alves et al., 2009), although other work has
not shown these differences (Baba et al., 2005).
These discrepancies may be instructive in their own right how-
ever, as studies that have found a difference tend to have examined
younger patients, whilst those that report no signiﬁcant sex dif-
ferences in age at onset have focused more on patients that were
older when they presented with the disease, possibly reﬂecting an
interaction with menopause in females and a potential role for
peripheral gonadal steroids. The literature also holds contradic-
tions on sex differences in the rate of disease progression. On the
one hand, increasing symptom severity was reported to be similar
in males and females (Baba et al., 2005), whereas another study
found a slower rate of decline of motor impairment in women,
despite no evidence for a sex difference in concomitant neuro-
chemical changes (Haaxma et al., 2007). To some extent, these
contradictions may be explained by the ﬁndings that there are
numerous sex differences in the clinical characteristics of PD,with
females presenting with a milder PD phenotype, at least in the
early clinical stages (Shulman and Bhat, 2006; Haaxma et al., 2007;
Miller and Cronin-Golomb, 2010). For example, rigidity appears
more frequently in men than women, whereas more women
than men suffer dyskinesias and PD-associated depression; a sex-
speciﬁc pattern is also emerging for disease-associated cognitive
defects. The advent of new technologies to dissect the molecu-
lar neuropathology of PD may possibly provide a more objective
analysis of underlying sexual dimorphisms. Indeed, comparison
of gene expression proﬁles in laser dissected single SNc dopamine
neurons in post-mortem brains of control subjects and idiopathic
PD patients (late stage) indicate a clear impact of sex on both
the normal and degenerating pathway: For example in the healthy
brain genes involved in signal transduction and neuronal matu-
ration were up-regulated in women, whereas an up-regulation of
genes implicated in PD pathogenesis (alpha-synuclein, PINK-1)
was seen in men relative to women; in PD brains changes in genes
with protein kinase activity and genes associated with proteolysis
andWnt signaling predominate in women, whereas predominant
gene changes in men were seen for those involved in protein-
and copper-binding activities (Simunovic et al., 2010; Cantuti-
Castelvetri et al., 2007). These differences, as well as indicating a
basal sex bias, also suggest differences in themechanism of the dis-
ease process. Thus, on balance, evidence from a variety of sources
strongly supports the proposition that women are relatively pro-
tected from PD compared with men. They also highlight the fact
that the goal of understanding PD pathogenesis and, hence, the
development of improved treatments, requires a better knowledge
of the basis for sex differences in PD. In the next section we shall
argue for the key importanceof sex steroids,whichpotentlymodify
genetic and environmental inﬂuences.
GENES VS. SEX HORMONES AS CONTRIBUTORS TO THE SEX BIAS IN
PARKINSON’S DISEASE
Single nucleotide polymorphisms in several estrogen-related
genes, including estrogen receptors and aromatase (estrogen
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synthase), have been positively associatedwith PD (Westberg et al.,
2004; Hakansson et al., 2005; Chung et al., 2011; Palacios et al.,
2011). On the basis that estrogens may be neuroprotective, this
could have relevance for a sex bias, but understanding how single
nucleotide polymorphisms inﬂuence disease risk remains a chal-
lenge (Klein and Schlossmacher, 2007). Moreover, as single gene
effects account for so few PD cases, other factors must account for
sex differences. On a more general level, it is increasingly appre-
ciated that factors linked to the sex chromosomes could explain a
certain degree of sex bias that is present in the great majority of
common diseases (Kaminsky et al., 2006). Such effects could be
attributable to a direct effect ofY chromosomegenes or to differen-
tial expression of X chromosome genes due either to incomplete
X chromosome silencing, or to sex differences in the genomic
imprinting of X chromosome genes (Federman, 2006; van Nas
et al., 2009). However, although pre-clinical evidence suggests that
sex chromosome effects have a certain role to play in brain sex-
ual differentiation (Federman, 2006; van Nas et al., 2009), their
potential impact on disease susceptibility is not yet known. Other
factors, which could act directly or interact with genetic factors,
include life-style as a cause of sex differences in PD, with exposure
to agrichemicals and head trauma being examples of factors which
associate with a greater incidence in men (Wooten et al., 2004; Das
et al., 2011).
Overwhelmingly however, sex hormones are the major factors
that drive structural and functional sex differences in the nor-
mal brain, and are increasingly identiﬁed as key components in
inducing differential susceptibility to complex disease, probably
by inducing differences in the epigenetic regulation of autosomal
genes (Kaminsky et al., 2006). By far the greatest degree of atten-
tion has focused upon the role of estrogen and its potential for
neuroprotective actions, supported by several lines of epidemio-
logical and clinical evidence (Dluzen andHorstink, 2003; Shulman
and Bhat, 2006). For example, women who have undergone sur-
gical removal of the ovaries present a signiﬁcantly increased risk
of developing PD (Benedetti et al., 2001; Ragonese et al., 2006).
Circulating levels of estrogen also seem to be involved in modu-
lating PD symptom severity in pre-menopausal women, as the
disease burden has been shown to lessen during stages of the
menstrual cycle characterized by high circulating estrogen, and
to worsen at menses, when estrogen levels are lowest (Quinn and
Marsden, 1986). In accord with these ﬁndings, there are numer-
ous reports that estrogen-based hormone replacement therapy has
positive effects on PD symptom burden (Saunders-Pullman et al.,
1999; Tsang et al., 2000; Benedetti et al., 2001) and cessation of
therapy has been associated with a marked deterioration in symp-
toms (Sandyk, 1989). Such therapies have also been associated
with a decreased risk of developing PD (Currie et al., 2004; Liu
and Dluzen, 2007), although this is not a universal ﬁnding (Popat
et al., 2005), possibly because of the considerable variations in
hormone replacement treatment regimes (Wise et al., 2005).
The evidence discussed above supports the view that sex inﬂu-
ences the incidence and nature of the degenerative processes in
the NSDA pathway, and that sex hormones, speciﬁcally estrogens
in females, play a key role. However, clinical studies do not permit
investigations into the nature of estrogen’s actions or provide clues
as to potential hormonal inﬂuences in men. Furthermore, they
cannot distinguish between the effects of gonadally derived and
centrally generated steroids, which are receiving increasing promi-
nence as regulators of brain development, function, and behavior
in the vertebrate brain (Do Rego et al., 2009). Signiﬁcantly, recent
evidence suggests that neurosteroids (that is, steroids synthesized
in the CNS de novo or from peripherally derived precursors) are
abundant in nigrostriatal regions in human post-mortem brains,
with reports of altered levels in degenerative conditions, includ-
ing PD (Bixo et al., 1997; di Michele et al., 2003; Luchetti et al.,
2010). Therefore, pre-clinical experimental models of PD have
an important role to play, and will be discussed in the following
section.
EXPERIMENTAL PARKINSON’S DISEASE
ANIMAL MODELS
Many aspects of idiopathic PD are recreated in experimental ani-
mal models. The simplest of such models are produced by the
use of the neurotoxins 6-hydroxydopamine (6-OHDA), typically
administered directly to the NSDA pathway in rodents (Figure 1;
Dluzen,1997;Murray et al., 2003), and1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), which is given systemically in mice
FIGURE 1 | Experimental Parkinson’s disease created by unilateral
infusions of 6-hydroxydopamine (6-OHDA). Schematic representation of
placement of the lesions, under general anesthesia, into the left medial
forebrain bundle (left panel) and immunocytochemical detection 1–2weeks
later of tyrosine hydroxylase, the rate-limiting enzyme in dopamine
synthesis, to identify dopaminergic neurons through ﬁve levels (A–E) of the
substantia nigra pars compacta (right panel).
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and non-human primates (Miller et al., 1998; Dluzen and
Horstink, 2003), as well as centrally in non-human primates
(Morissette and Di Paolo, 2009; Fox and Brotchie, 2010). Both
toxins selectively kill dopaminergic cells through a combination
of oxidative stress and the inhibition of mitochondrial respira-
tion (Glinka et al., 1996; Blum et al., 2001; Simola et al., 2007).
Methamphetamine has also been used to create nigral lesions in
mice, although the similarities to parkinsonian degeneration have
been less well characterized (Dluzen et al., 2002; Dluzen and Liu,
2008).Whilst such models are limited in that they cannot recreate
the true (unknown) underlying cause of PD, they have proven of
very great value in aiding our understanding of its symptoms and
pathology,andhavebeen essential in thedevelopmentof therapeu-
tic agents for the treatment of the condition (Lane and Dunnett,
2008; Fox and Brotchie, 2010; Potashkin et al., 2010). As such they
are of great utility in studying the potential neuroprotective role of
sex steroid hormones, and have provided signiﬁcant insights into
the interactions of estradiol with the degenerating nigrostriatal
dopaminergic pathway.
SEX DIFFERENCES IN EXPERIMENTAL PARKINSON’S DISEASE
The existence of sex differences in susceptibility to neurotoxic
lesioning is widely reported in various animal models of PD,
recapitulating the differences seen clinically. For example, clear
sex differences are seen in the extent of both dopamine loss in
the striatum and dopaminergic neuron loss in the SNc following
administration of 6-hydroxydopamine (6-OHDA) to rats (Table 1;
Table 1 | Sex differences in experimental PD.
Lesion size (% loss)
Males Females (proestrus)
SNcTH-IR 35.9±3.8 20.8±3.0*
Striatal DA levels 48.4±5.6 17.0±4.3*
∗p<0.05 Compared with males.
Sex-dependent degeneration in the nigrostriatal dopaminergic pathway in
response to 6-hydroxydopamine (6-OHDA) in rats. As described in detail else-
where (Murray et al., 2003; McArthur et al., 2007) animals received unilateral,
slow infusions (4μl) of 6-OHDA (1μg), or vehicle into the left medial forebrain
bundle (MFB) connecting the substantia nigra pars compacta (SNc) and striatum.
Results are expressed as the loss of cells showing positive immunoreactivity for
tyrosine hydroxylase (TH-IR, indicating the rate-limiting enzyme in dopamine syn-
thesis) in the lesioned (left) SNc, or the loss of dopamine (DA) in the lesioned
(left) striatum, expressed as a percentage of TH-IR cells or DA levels in the con-
tralateral, unlesioned (right) striatum, respectively. Separate analyses of male and
female SNc and striata established that there were no signiﬁcant effects of either
vehicle or 6-OHDA infusions into the left MFB on values for TH-IR cell numbers
or DA levels, respectively, in the unlesioned (right) side, thereby validating the
use of the unlesioned side as an internal control for quantiﬁcation of the toxin-
induced lesion. Absolute control values revealed a signiﬁcantly greater number
ofTH-IR cells in males compared with females at all levels through the SNc (Mur-
ray et al., 2003), with estimated total cell counts of 7396±184 and 6637±243,
respectively (p<0.05), whereas control values for striatal DA levels were similar
in males (110±5ng/mg tissue wet weight) and females (113±6.6 ng/mg tissue
wet weight; Murray et al., 2003).
Figure 2 control, gonad-intact groups; Murray et al., 2003; Gillies
et al., 2004). Moreover, the progressive loss of dopaminergic cells
over a 5-week period post-lesioning was consistently greater in 6-
OHDA-treated male rats, conﬁrming a true sex difference rather
a difference in the rate of neurodegeneration (Moroz et al., 2003).
Similar sex differences in the extent of SNc and striatal lesions are
seen in mice treated with MPTP or MA, with females being rel-
atively protected (Miller et al., 1998; Dluzen, 2000; Yu and Liao,
2000; Liu and Dluzen, 2007). These differences are present fol-
lowing partial lesions (<60%) of the nigrostriatal pathway using
sub-maximal doses of 6-OHDA, but with larger lesions (70–90%)
sex differences are no longer apparent (Gillies et al., 2004; Gillies
and McArthur, 2010b). Together, these pre-clinical ﬁndings cor-
roborate the clinical studies suggesting that females may be more
able to resist the onset and/or progression of the neurodegener-
ative lesions. However, they also demonstrate that the degree of
intrinsic neuroprotection in the female brain can be over-ridden
once neurodegeneration reaches a certain extent. Additionally,
these studies demonstrate that the use of an experimental regime
of sub-maximal lesions in the NSDA pathway, considered to be
a model of pre-clinical/early stage PD (Schwarting and Huston,
1996), has potential for investigating the factors that provide the
FIGURE 2 | Manipulation of the hormone environment exerts
sex-specific effects on striatal lesions induced by 6-hydroxydopamine
(6-OHDA). Male and female rats underwent bilateral gonadectomy (GDX)
or sham operation (Gonad-intact) followed immediately, while still under
anesthesia, by subcutaneous implantation of a pellet, containing either
estradiol (replaced to proestrus levels), 5α-dihydrotestosterone (to mimic
physiological androgen levels), or a placebo pellet (full details in Murray
et al., 2003). Approximately 1week later all animals received a unilateral
infusion of 6-hydroxydopamine (6-OHDA; 1μg) into the left medial forebrain
bundle and, after killing 2weeks later, brains were processed to assess
lesion size. Results represent the percentage striatal dopamine (DA)
remaining in the lesioned (left) side compared with the contralateral,
unlesioned (right) side. Sham-operated animals (Gonad-intact, ) are taken
as controls. (A) Following ovariectomy () levels of DA in the female
striatum were signiﬁcantly reduced compared with their sham-operated
counterparts. This effect was unaltered by treatment with the
non-aromatizable androgen, dihydrotestosterone (DHT, ), but was
reversed by estradiol (E2, ). (B) Following orchidectomy (), levels of DA
in the male striatum were signiﬁcantly greater than their sham-operated
counterparts (). This effects was unaffected by treatment with DHT (),
but was reversed by estradiol (E2, ). ∗p<0.05 Vs. gonad-intact; #p<0.05
vs. GDX. (Modiﬁed from Murray et al., 2003).
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female advantage, hence revealing novel therapeutic approaches
to delay disease onset and/or progression.
IMPACT OF PERIPHERAL SEX STEROID HORMONES ON STRIATAL
LESION SIZE
The reduction in the levels of dopamine and its metabolites in the
striatumarewidely used as indicators of themagnitude of destruc-
tion (size of lesion) induced in rodent models of PD. Despite
the greater male susceptibility to PD, the vast majority of stud-
ies have focused on the neuroprotective effects of estrogens in
female rodents and, to a lesser extent, female non-humanprimates.
However, convergent evidence indicates that gonadal factors play
a different role in males (Gillies et al., 2004; McArthur et al., 2007;
Gillies andMcArthur, 2010a),whichmerits separate consideration
of the sexes.
Females
The loss of striatal dopamine in the 6-OHDA-partially lesioned
nigrostriatal system is far greater after ovariectomy than in gonad-
intact female rats (Murray et al., 2003) an effect which can be
reversed by replacement of estradiol to physiological levels prior
to lesioning (Figure 2A; Dluzen, 1997; Murray et al., 2003; Ferraz
et al., 2008). Estradiol treatment of ovariectomized animals also
reduces striatal dopamine depletion induced by MPTP in mice
(Miller et al., 1998; Dluzen and Horstink, 2003) and non-human
primates (Morissette and Di Paolo, 2009), or by MA in mice (Yu
and Liao, 2000). Equally, female rats lesioned with any of these
three toxins at proestrus, when estrogen levels are maximal, exhib-
ited signiﬁcantly smaller losses of striatal dopamine than similar
animals lesioned at diestrus, the period of the estrus cycle when
estrogen levels are at their nadir (Yu and Liao, 2000; Datla et al.,
2003; Dluzen and Horstink, 2003). However, just as the female
advantage in experimental PD is lost as lesion size approaches
or exceeds approximately 60%, so is the neuroprotective effect of
estradiol lost with larger lesions (Cordellini et al., 2011). More-
over, replacement of estradiol to high, supraphysiological levels
may fail to protect or even worsen lesion size (Ramirez et al.,
2003; Bourque et al., 2009; Cordellini et al., 2011). These stud-
ies demonstrate that the levels of circulating estradiol prevailing at
the time of injury are critical and that physiological levels, whether
endogenous or administered exogenously, have protective capac-
ity in the partially injured female NSDA system. They therefore
support the prevailing view that sex differences in PD could be
attributable largely to the protective role of gonadal factors,namely
estradiol.
Males
Unlike in females, gonadectomy signiﬁcantly reduced striatal
lesion size in male rats exposed to sub-maximal doses of 6-
OHDA (Figure 2B). Although some studies in mice report that
castration had no signiﬁcant effect on neurotoxin-induced stri-
atal dopamine loss, (Dluzen et al., 1994; Yu and Wagner, 1994;
Gao and Dluzen, 2001), others found that testosterone treatment
of either intact or gonadectomized CD-1 male mice worsened
striatal dopamine loss in animals with mild/moderate (40%)
lesions (Dluzen et al., 1994; Lewis and Dluzen, 2008). On bal-
ance, these ﬁndings suggest that gonadally derived testosterone
has detrimental effects in experimental PD, which appears to be a
cross-species phenomenon. However, with more extensive lesions
(70%) testosterone treatment caused no further loss of striatal
dopamine (Dluzen et al., 1994). Thus, although the effects of
gonadally derived hormones are opposite in males and females, in
both sexes hormonal inﬂuences appear to have a signiﬁcant effect
only in experimental models mimicking the pre-clinical/early
phases of the degenerative process. Despite the general ﬁnding
that estradiol provides universal protection against dopamine loss
in experimental PD in female mice and rats, whether estrogens
are protective in males is more equivocal, possibly because of dif-
ferences in species, strain, neurotoxin, and hormone treatment
regimes employed in various studies. For example, in the highly
sensitive C56Bl/6 mouse strain, estradiol may protect male mice
against MPTP-induce striatal lesions (Dluzen, 1996; Ekue et al.,
2002), whereas it lacked any protective capacity against MA tox-
icity (Gao and Dluzen, 2001; Yu et al., 2002). Moreover, in the
6-OHDA rat model, treatment of castrated males with physiologi-
cal levels of estradiol exacerbated lesion size, thereby reversing the
effects of gonadectomy, whereas the non-aromatizable androgen,
dihydrotestosterone (DHT), had no effect on striatal dopamine
loss and failed to reverse the effects of gonadectomy (Figure 2;
Murray et al., 2003). These ﬁndings suggest that any inﬂuences
of circulating testosterone to promote degeneration in the male
NSDA system operate only after its conversion to estradiol by aro-
matase enzymes, which are prevalent in the striatum (Kuppers
et al., 2000).
The preceding observations support the view that detrimen-
tal effects of gonadal factors in the male NSDA system, as well
as protective effects of ovarian factors in females compound to
create sex differences in striatal susceptibility to injury. Further-
more, they reveal that estrogen therapy has opposite effects on
striatal dopamine loss inmales (increased) and females (reduced).
Together, these pre-clinical ﬁndings complement the clinical evi-
dence (discussed above) for sexual dimorphisms in the mecha-
nisms underlying NSDA degeneration and highlight the potential
for centrally generated as well as systemic sex steroid hormones to
critically inﬂuence these processes. Furthermore, they reveal that
the reported clinical beneﬁts of estrogens in the female sex may
not simply translate to the opposite sex.
IMPACT OF PERIPHERAL SEX STEROID HORMONES ON SNc
LESION SIZE
It is implicit in studies of experimental PD that the extent of
striatal dopamine loss equates with the extent of dopaminergic
neuron loss in the SNc, as corroborated by the data in Table 1,
showing similar sex differences in lesion size at both cell body
and terminal levels. Therefore, the majority of studies measure
only striatal dopamine levels. However, despite substantial evi-
dence that systemic hormonal status affects striatal dopamine loss
(discussed above), gonadectomy, and replacement with estradiol
or DHT did not affect the loss dopaminergic neurons in males
(McArthur et al., 2007) or females (Ferraz et al., 2003, 2008;Moroz
et al., 2003; McArthur et al., 2007) exposed to 6-OHDA. More-
over, dopaminergic cell numbers in the normal SNc, which are
signiﬁcantly greater in males compared with females (see legend
Table 1; Murray et al., 2003; Gillies et al., 2004; Dewing et al., 2006;
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McArthur et al., 2007), were not affected by gonadectomy, with or
without hormone replacement, in either sex. These studies suggest
that the inherent sex differences in dopaminergic cell numbers, as
well as sex differences in dopaminergic cell loss in experimental
PD, are not hormone-dependent, and that hormonal inﬂuences on
striatal dopamine depletion occur independently of dopaminergic
cell survival.
SEX HORMONE INFLUENCES ON ADAPTATION VS. SURVIVAL:
PHYSIOLOGICAL AND SUPRAPHYSIOLOGICAL EFFECTS
The evidence discussed thus far demonstrates a dissociation of the
effects of physiological levels of circulating estradiol at the level of
the cell body and nerve terminals in the partially injured NSDA
system in both males and females, although these effects are sex-
ually dimorphic. We therefore need to ask how systemic estradiol
can preserve striatal dopamine levels in the NSDA pathway after
injury in females, but not males, without affecting dopaminergic
neuron numbers in either sex.
Available evidence supports the view that hormonal inﬂu-
ences on the activity of the surviving neurons rather than on
neuron survival may be one explanation for these observations
(McArthur et al., 2007; Gillies and McArthur, 2010a,b). In both
clinical and experimental PD the surviving neurons and asso-
ciated basal ganglia circuitry are known to have a remarkable
capacity for compensation, and this is thought to account for the
ﬁnding that overt motor symptoms may not be apparent until
around 80% of striatal dopamine and 60% of SNc perikarya
are lost (Castaneda et al., 1990; Song and Haber, 2000; Bezard
et al., 2001, 2003; Bassilana et al., 2005). The adaptive mechanisms
include increased tyrosine hydroxylase expression leading to syn-
thesis and release of dopamine, maintaining striatal functionality.
Notably, circulating estradiol (endogenous and exogenous) pro-
motes all these parameters (McDermott et al., 1994; Pasqualini
et al., 1995; Becker, 1999; Ohtani et al., 2001; Serova et al., 2004;
Dluzen, 2005), as well as striatal dopamine turnover (McArthur
et al., 2007) in females, but not males. Proestrus levels of estra-
diol are also far more effective in the female compared with the
male striatum in suppressing the density of the dopamine trans-
porter (McArthur et al., 2007), which is both a critical regulator
of dopaminergic neuron dynamics and a gateway for the entry
of neurotoxins into dopaminergic neurons. Additionally, estradiol
replacement promotes behavioral recovery after 6-OHDA lesions
in female rodents, but fails to do so in males (Tamas et al., 2005).
Hence, a combination of physiological levels of estradiol in the
systemic circulation with a mild/moderate injury to the NSDA
would render females, but not males, more able to preserve stri-
atal dopamine levels and adapt to injury, without changing cell
numbers.
Less evidence is available to explain the origins of the hormone-
independent sex differences in dopaminergic cell numbers in the
intact (males> females) and injured SNc (males< females; Mur-
ray et al., 2003; Dewing et al., 2006; McArthur et al., 2007). Of
potential relevance is the discovery that a proportion of dopamin-
ergic neurons within the murine SNc co-express the Sry gene (the
sex determining region of theY chromosome;Dewing et al., 2006),
which was previously thought to be relevant solely to ensuring
testicular differentiation in the embryo. Transient suppression of
this gene in the adult mouse brain not only reduced the num-
bers of dopaminergic neurons in the male SNc to those seen in
the normal female SNc, but also compromised ﬁne motor con-
trol, emphasizing the relevance of this co-expression for NSDA
functionality (Dewing et al., 2006). However, the impact of Sry on
dopaminergic neuron survival in the injured SNc remains to be
determined.
Despite the foregoing discussion, it must be acknowledged that
under certain circumstances estrogens have been reported to pro-
tect against the neurotoxin-induced loss of nigral dopaminergic
cells (DeGiorgio et al., 2002;Quesada andMicevych,2004). Gener-
ally, however, this requires high, pharmacological doses which are
known to activate various non-speciﬁc processes that are common
to neuroprotection against many types of injury throughout the
brain, including anti-oxidant activity and effects on genes involved
in regulating apoptosis (Green and Simpkins, 2000; Hurn and
Macrae, 2000; Garcia-Segura et al., 2001; Behl, 2002; Murray et al.,
2003; Dewing et al., 2006; Brann et al., 2007; McArthur et al.,
2007; Wise et al., 2009). Therefore, we have proposed that neu-
roprotection afforded by supraphysiological levels of estradiol in
the systemic circulation is not speciﬁc to the degenerating NSDA
system, whereas levels within the physiological range uniquely
modify NSDA activity rather than nigral cell survival (Gillies and
McArthur, 2010b).
IMPACT OF CENTRALLY GENERATED SEX STEROIDS IN
EXPERIMENTAL PD
Incontrovertible evidence now shows that in addition to respond-
ing to sex steroid hormones, the brain itself is a steroidogenic
organ, synthesizing neurosteroids (estrogens, progestogens, and
androgens) de novo from cholesterol or after metabolism of pre-
cursors, which may derive from peripheral sources (Do Rego
et al., 2009). Accordingly, the complex series of enzymes required
for steroid biosynthesis are all found in the brain, with dis-
crete distributions in neurons and glia, which are thought to
act co-operatively in the production of a range of steroids to
inﬂuence brain development,physiology, and pathology (Mensah-
Nyagan et al., 1999; Zwain and Yen, 1999; Pelletier, 2010). The
most important of these regarding the potential neuromodu-
latory and neuroprotective actions of estrogen is the enzyme
aromatase (cytochrome P450 19A1, EC 1.14.14.1; Azcoitia et al.,
2010, 2011; Boon et al., 2010), which catalyzes the synthesis of
various isoforms of estrogens, including estradiol, estrone, 2-
hydroxy estradiol, and the 17α- and 17β- isomers (Saldanha et al.,
2009). Importantly, these enzymes are present in both male and
female brains, although with some sex differences in distribution
(reviewed by Balthazart in this issue). In particular, concentra-
tions of estrogen in male brains have been estimated as being at
least six times greater than in the plasma (Mukai et al., 2006),
and may potentially be even greater at local sites due to the
concentration of the hormone at the synapse (Balthazart et al.,
2002).
In the normal brain it is thought that aromatase expression
occurs primarily in neurons, where it may have a role in modu-
lating neurotransmission (Balthazart and Ball, 2006). Aromatase
activity, and hence the production of estrogens, has a further
important role in the response to neural injury, as seen in a
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variety of experimental models (Garcia-Segura, 2008). For exam-
ple, studies of hippocampal excitotoxicity revealed signiﬁcantly
greater neuronal loss in the absence of effective aromatase activity,
whether through pharmacological or genetic ablation (Azcoitia
et al., 2001). Moreover, up-regulation of aromatase expression,
principally in astrocytes, has been reported following a diverse
range of neural injuries, indicating a protective role in male and
female brains (Azcoitia et al., 2003, 2005, 2010; Carswell et al.,
2005; Garcia-Ovejero et al., 2005; Garcia-Segura, 2008). A role for
aromatase in the NSDA system has received less attention, but
the enzyme is present in the undamaged striatum throughout life
(Kuppers and Beyer, 1998; Kipp et al., 2006). Evidence suggests
that it plays an important role in nigrostriatal development as one
feature characterizing the aromatase knock-out mouse is a dra-
matic decrease in SNc dopaminergic neuron number and striatal
dopaminergic ﬁber innervation when compared with wild-type
littermates (Morale et al., 2008). A functional link between aro-
matase and the nigrostriatal dopaminergic system is also suggested
by the ﬁnding that administration of the aromatase inhibitor anas-
trozole to the otherwise uninjured nigrostriatal pathway signiﬁ-
cantly enhanced striatal dopamine content (McArthur et al., 2007).
Furthermore, aromatase appears to play a protective role follow-
ing neurotoxic lesioning of the nigrostriatal system (Figure 3).
Infusion of anastrozole into the medial forebrain bundle of male
rats prior to administering 6-OHDA caused a signiﬁcant poten-
tiation of dopamine loss in the degenerating striatum (McArthur
et al., 2007). Studies using the aromatase knock-out mouse also
suggest that central aromatase activity protects females against
neurotoxin-induced striatal dopamine depletion (Morale et al.,
2008). Interestingly, anastrozole failed to inﬂuence the loss of
FIGURE 3 | Inhibition of striatal aromatase activity augments the
lesion size following administration of 6-hydroxydopamine (6-OHDA).
Administration of the selective aromatase inhibitor anastrozole (7μg) to the
left medial forebrain bundle of male rats concurrently with 1μg
6-hydroxydopamine signiﬁcantly increased the degree of striatal dopamine
loss seen 1week later. ∗p<0.05 Vs. vehicle-treated group; +p<0.05 vs.
anastrozole +6-OHDA group. (Modiﬁed from McArthur et al., 2007).
SNc dopaminergic neurons in the partially damaged NSDA path-
way (McArthur et al., 2007). Together, these observations support
the view that in males centrally generated endogenous estrogens
primarily promote plastic/adaptive compensatory mechanisms
within the surviving dopaminergic neurons to maintain striatal
dopamine content, without affecting cell survival, in a manner
similar to that described above for systemic estrogens in females
(Figure 2, see Impact of Peripheral Sex Steroid Hormones on Stri-
atal Lesion Size and Impact of Peripheral Sex Steroid Hormones
on SNc Lesion Size). Additionally, these ﬁndings reveal that in
males estradiol can have opposite effects on striatal susceptibility
to injury depending on its central or systemic origin to reduce or
worsen damage, respectively.
DIFFERENTIAL EFFECTS OF PERIPHERAL AND CENTRAL SEX STEROID
HORMONES
Further studies are required to solve this puzzle, but it seems likely
that there are different modes of action for centrally generated
and systemic steroids (Prange-Kiel and Rune, 2006). Hence, we
hypothesize that aromatase activity in the area of discrete neu-
ronal injurywill be responsible for the local productionof estradiol
which acts directly on the nigral dopaminergic neurons to activate
protective, compensatory mechanisms in both males and females
(Table 2). In contrast, gonadal or exogenous steroids administered
Table 2 | Summary of potential modes of action of peripheral and
central sex steroid hormones on the nigrostriatal dopaminergic
(NSDA) system in male and female brain.
Source of steroids Influence on activity/adaptive
capacity of NSDA neurons
Males Females
Systemic sex steroid hormones
Direct effect Increased Increased
Indirect effect Decreased Increased
Centrally generated estrogens
(direct effect)
Increased Increased
Systemically administered estradiol (exogenous) or endogenous, peripherally
derived estradiol in females (ovarian production) and its precursor in males (tes-
ticular production of testosterone), as well as centrally generated estrogens
(up-regulation of aromatase in response to injury) have the potential to act directly
on the nigral dopaminergic neurons to up-regulate activity/adaptive capacity in
the surviving neurons of the partially injured NSDA system. However, peripher-
ally derived estradiol and its precursors also have the potential to act indirectly on
sexually differentiated networks interactingwith and regulating theNSDAsystem,
resulting in an up-regulation of NSDA activity in females, but a down-regulation
in males. These competing activities ultimately promote more effective adaptive
responses in the partially injured NSDA system in females, whereas inmales they
offer no protection, and may even exacerbate striatal lesions. This hypothetical
schema can explain why gonadal factors and exogenous estradiol have the ability
to preserve striatal dopamine levels in experimental Parkinson’s disease only in
females, but not males, whereas estradiol generated in the region of the partially
injured NSDA pathway reduces striatal dopamine loss in both sexes (see Impact
of Peripheral Sex Steroid Hormones on Striatal Lesion Size to Impact of Centrally
Generated Sex Steroids in Experimental PD).
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peripherally can freely access most brain regions, including net-
works interacting with and regulating the NSDA system. These
systems are known to be sexually differentiated and may therefore
exert indirect, sex-speciﬁc inﬂuences on its activity and, hence,
capacity to adapt to injury. In males the net effect would be an
increased striatal vulnerability to 6-OHDA which over-rides any
beneﬁcial effects of locally synthesized estrogens (including those
derived from circulating testosterone), whereas in females the net
effect is protective. In support of this, numerous examples where
systemic estrogen promotes NSDA activity in females but not
males were given in Section “Impact of Peripheral Sex Steroid
Hormones on SNc Lesion Size.” Although this could be due to
direct effects on dopaminergic neurons, estrogen-sensitive sexu-
ally dimorphic input pathways could be targeted. For example,
noradrenergic transmission from the locus coeruleus exerts posi-
tive inﬂuences onneurotransmission and adaptive responses in the
injured NSDA system (Marien et al., 2004), but tyrosine hydrox-
ylase expression in this pathway is up-regulated by circulating
estradiol in femalemice, but down-regulated by testosterone (after
conversion to estradiol) in male mice (Thanky et al., 2002). The
striatal medium spiny neurons, which provide critical GABAer-
gic interneuron regulation of the basal ganglia, are also sexually
differentiated targets for estradiol, which suppresses their neg-
ative inﬂuence on dopaminergic terminals (increasing release)
in females, but not males (Hu et al., 2004, 2006; Schultz et al.,
2009). Other sexually differentiated, estrogen-sensitive networks
that couldmodify adaptations in the injuredNSDA system include
the mesocortical dopaminergic pathways (Kritzer and Creutz,
2008) and the serotonergic system of the dorsal raphe (Klink et al.,
2002). Whatever the precise mechanisms involved, together, these
observations highlight brain aromatase as an attractive therapeutic
target in both sexes.
A question remains as to the cellular source of aromatase
activity, and hence the locally derived estrogen, in the lesioned
striatum. Aromatase expression has been identiﬁed within devel-
oping striatal neurons (Kuppers and Beyer, 1998), but there is a
lack of information on its presence in the injured adult NSDA
system. However, the balance of evidence from other forms
of neuronal injury, including penetrative trauma, excitotoxicity,
and hypoxia/ischemia, would favor its up-regulation in reac-
tive glia, especially astrocytes (Garcia-Segura et al., 1999; Wynne
and Saldanha, 2004; Carswell et al., 2005; Garcia-Ovejero et al.,
2005; Azcoitia et al., 2010) which are considered the most active
steroidogenic cells in the rat brain (Zwain and Yen, 1999).
GLIA AS PRODUCERS OF AND TARGETS FOR ESTROGEN
Injury to the brain, whether by trauma, ischemia, infection, or
degenerative diseases, such as Parkinson’s and Alzheimer’s, trig-
gers an immune response (Lucas et al., 2006; Klegeris et al., 2007).
Although this differs in important respects from the peripheral
immune response in ways that yet need to be fully deﬁned, brain
innate immunity shares the same purpose of host-defense which,
if excessively or chronically activated can become damaging to
the host and exacerbate on-going disease processes (Rogers et al.,
2007). Two types of glial cells, the astrocytes, and microglia, play
critical, active, and co-operative roles in mounting and regulat-
ing brain immune responses (Farina et al., 2007) and, depending
on the phase of the response (activation vs. resolution) and nature
of the stimulus, exhibit both pro-inﬂammatory (potentially harm-
ful) and anti-inﬂammatory (protective) features (Minghetti, 2005;
Lucas et al., 2006). Thus augmentation of glial protective and
repair processes aswell as suppression of their neurotoxic potential
are attractive novel therapeutic strategies. Notably, steroid hor-
mones, especially estrogens, have been credited with the powerful
ability to regulate the balance of astrocytic and microglial activity
toward a favorable pro- vs. anti-inﬂammatory status (Garcia-
Ovejero et al., 2005; Marchetti et al., 2005; Block et al., 2007;
Tapia-Gonzalez et al., 2008; Vegeto et al., 2008; Arevalo et al.,
2011). Moreover, just as peripheral immune functions are sexually
dimorphic in humans and animals, regulated to a large degree by
sex hormones (Azevedo et al., 2001), evidence is emerging for sex
differences in the neuroimmune response (Santos-Galindo et al.,
2011). Thus, knowledge of hormonal inﬂuences on glia is essential
for the effective design of new treatments as well as our under-
standing of sexual dimorphisms in CNS disorders. Importantly,
endogenous regulation of glial reactivity by sex steroids may come
both fromperipheral, gonadally derived sources as well as the CNS
glia themselves.
Astrocytes
Classically, astrocytes, the most abundant type of cell within the
brain parenchyma, have been thought of as merely providing
structural andmetabolic support to neurons.Over the past decade,
however, it has steadily become clear that they performmany other
functions, such as the regulation of and participation in neuro-
transmitter release and synaptic function (Halassa and Haydon,
2010). Increasing evidence suggests that they may also play an
important role in regulating the neuronal response to injury (Bar-
res, 2008), with reactive astrogliosis being a feature of many CNS
disorders, representing context-dependent inﬂuences that have
the potential to be both beneﬁcial or detrimental (Hamby and
Sofroniew, 2010). The regulatory mechanisms are complex and
not fully understood, but it is particularly relevant to the present
discussion that astrocytes canbothproduce estrogens (as discussed
above, seeDifferential Effects of Peripheral andCentral Sex Steroid
Hormones; Zwain and Yen, 1999) and respond to this sex steroid
hormone.
Up-regulation of astrocyte aromatase activity at sites of injury,
and the associated increase in local synthesis of estradiol,may trig-
ger a variety of protective mechanisms in vulnerable neurons that
are considered general, non-speciﬁc actions of estrogens. These
include modiﬁcation of apoptotic pathways and anti-oxidant
activity, that have been extensively reviewed elsewhere (Green and
Simpkins, 2000; Garcia-Segura et al., 2001; Behl, 2002; Brann et al.,
2007; Garcia-Segura, 2008; Nilsen, 2008; Saldanha et al., 2009). In
addition to being a likely local source of aromatase/estrogens in the
damaged brain, astrocytes could also contribute to sex differences
in damage/repair processes. For example, one study, using primary
astrocyte cultures derived from the neonatal rat cortex, showed
that females have a greater capacity for aromatization and estradiol
production compared with males; it remains to be seen whether
this effect is region-speciﬁc and/or age-dependent. Sex differences
inneurosteroid levels have,however,been reported in various areas
of the normal and injured adult rat brain (Cosimo Melcangi and
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Garcia-Segura, 2010; Pesaresi et al., 2010), and neurosteroid levels
are changed in affected regions in several models of neurode-
generation, including the striatum in the 6-OHDA-lesioned rat
model of PD (Melcangi et al., 2010). Together, these ﬁndings sug-
gest that differing capacities for constitutive and/or injury-induced
neurosteroid production could contribute to sex differences in the
incidence and/or manifestation of CNS pathologies.
As well as targeting neurons, astrocyte-derived estrogens also
exert important effects on glia, namely astrocytes themselves and
microglia, the macrophage-like, innate immune cells of the brain.
The evidence for constitutive astrocyte expression of ERs is contra-
dictory (Azcoitia et al., 1999; Blurton-Jones and Tuszynski, 2001;
Milner et al., 2001, 2005), but it appears that a key part of the
neural response to various types of injury seen in rodents and
primates includes an up-regulation of ERα as well as aromatase
within astrocytes (Garcia-Segura et al., 1999; Blurton-Jones and
Tuszynski, 2001; Carswell et al., 2005; Garcia-Ovejero et al., 2005).
Although ER expression in the astrocytes of the damaged NSDA
pathway has not been speciﬁcally studied, under normal condi-
tions ERα is present at low levels in the striatum and SNc, but
not in dopaminergic cells, whereas ERβ was not detected in the
striatum (Shughrue, 2004), but was found to be present in 40% of
nigral dopaminergic neurons as well as in 30% of astrocytes in the
female rat (Quesada et al., 2007). Importantly, in addition to their
neuroprotective and neurotrophic activities, astrocytes may also
release factors such as pro-inﬂammatory cytokines, chemokines,
and reactive oxygen/nitrogen species in response to injury which,
although necessary for local resistance and repair mechanisms, if
present in excess for prolonged periods can become neurotoxic
and are thought to contribute to the progression of neurodegen-
erative disorders such as PD (Marchetti et al., 2005; Morale et al.,
2006;Yokoyama et al., 2011). Thus, the orchestrated up-regulation
of both aromatase and ERs in reactive astrocytes may serve as a
negative feedback regulator of the astrocytic response, thereby
representing an important component of the brain’s response
to injury. In direct support for this view, in vitro studies have
demonstrated that estradiol treatment reduces the production of
cytokines and reactive oxygen species by astrocytes from many
brain regions, including the midbrain, following inﬂammatory
challenge (Kipp et al., 2007; Cerciat et al., 2010; Santos-Galindo
et al., 2011). Furthermore, in vivo studies using the MPTP-treated
mouse model of PD, showed that circulating estradiol (endoge-
nous or exogenous) can down-regulate injury-induced astrogliosis
and astrocytic production of inducible nitric oxide synthetase,
which correlatedwith its protective effects (Morale et al., 2006; Tri-
panichkul et al., 2006). Although not in the context of PD, a recent
study has provided an elegant demonstration that astrocytes are,
indeed, the mediators of estrogenic neuroprotection by showing
that conditional deletion of ERα from astrocytes, but not from
neurons, prevented the neuroprotective effects of systemic ERα
ligands in murine experimental autoimmune encephalomyelitis
(Spence et al., 2011).
Microglia
Microglia are critical components of the neuroimmune, host-
defense response to injury- and disease-induced neurodegen-
eration. They constantly monitor the brain microenvironment
for signs of tissue damage or infection, whereupon they rapidly
become activated and co-ordinate the brain’s immune response
(Nimmerjahn et al., 2005). This involves production of a host of
pro-inﬂammatory and pro-oxidant mediators which, if the neu-
roinﬂammatory response is not curtailed, will exacerbate rather
than protect against neural damage, leading to a detrimental neu-
rological outcome (Hirsch et al., 1998; Block et al., 2007; Rogers
et al., 2007; Vegeto et al., 2008). Their signiﬁcance in PD is under-
scored by the presence of high numbers of microglia in close
proximity to degenerating neurons of post-mortem parkinson-
ian brains (McGeer et al., 1988; Banati et al., 1998; Hirsch et al.,
1998; Orr et al., 2005; Hamza et al., 2010; Halliday and Stevens,
2011). Thesemicroglia express high levels of pro-oxidant enzymes
including inducible nitric oxide synthase (Hunot et al., 1996),
NADPH oxidase, and cyclo-oxygenase (Knott et al., 2000), thereby
representing an important source of the reactive oxygen species
known to contribute to oxidative stress in the dopaminergic neu-
rons of the parkinsonian SNc (Shadrina et al., 2010). Although
the steroidogenic capacity of microglia has received relatively lit-
tle attention compared with that of astrocytes, they do express
the machinery for steroidogenesis (Garcia-Ovejero et al., 2005),
including steroid converting enzymes that would enable them
to produce estrogenic compounds from precursors (Gottfried-
Blackmore et al., 2008), and they also express ERs (Vegeto et al.,
2003; Baker et al., 2004; Sierra et al., 2008). Together, these obser-
vations suggest thatmicroglia contribute to the neurodegenerative
process in PD and could be targets for andmediators of the neuro-
protective effects of estrogens (Garcia-Ovejero et al., 2005; Vegeto
et al., 2008). In support of this, studies using either primary mes-
encephalic neuronal cultures or dopaminergic cell lines (Liu et al.,
2005; McArthur et al., 2010) have shown that microglia activated
by treatment with bacterial lipopolysaccharide (LPS) can cause the
death of dopaminergic neurons through the release of toxic fac-
tors such as reactive oxygen/nitrogen species and TNFα, an effect
that can be prevented by co-treatment with estradiol (Liu et al.,
2005). Similar effects have been reported in vivo, where admin-
istration of estradiol to ovariectomized mice treated with MPTP
signiﬁcantly suppressed microglial production of iNOS and nitric
oxide, limiting striatal dopamine loss (Morale et al., 2006).
Despite the principal research focus on suppressing the poten-
tially harmful phenotypes induced by reactive gliosis in neuronal
injury, glia, and microglia in particular, perform the critically pro-
tective role of removing dead or dying cells before they can enter
secondary necrosis and become pro-inﬂammatory foci (Neumann
et al., 2009). This removal of apoptotic cells by phagocytosis is an
important component of inﬂammatory resolution, as their engulf-
ment induces anti-inﬂammatorymicroglial activation and actively
contributes to repair and the restoration of homeostasis. In order
to investigate this phenomenon we have developed an in vitro
system comprising a microglial cell line and a dopaminergic neu-
ronal cell line inwhich apoptosis can be induced by treatment with
the selective dopaminergic neurotoxin, 6-OHDA (McArthur et al.,
2010). In thismodel, apoptotic, neuron-like cells are phagocytosed
by the microglia, a process enhanced in a dose-dependent manner
by estradiol (Figure 4), suggesting that promotion of microglial
phagocytosis is yet another pathway by which estrogens may serve
as neuroprotective agents in PD.
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FIGURE 4 | Estradiol enhances microglial phagocytosis.We used our
established in vitro model of co-cultures of the murine microglial cell line
BV2 and the rat neuron-like cell line PC12 to investigate phagocytosis, for
full details see (McArthur et al., 2010), to study the effects of estradiol
treatment upon the removal of apoptotic neurons. (A)Treatment of BV2
microglia for 16 h with 100 nM 17β-estradiol had no effect upon the
phagocytosis of vehicle-treated, non-apoptotic PC12 cells (), but
signiﬁcantly increased the number of microglia actively phagocytosing
apoptotic, 6-OHDA-treated PC12 cells () when compared with untreated
control microglia, ∗p<0.05 vs. untreated microglia. (B)Typical example of
BV2 microglia phagocytosing CMFDA-labeled, green ﬂuorescent PC12 cells
after 6-hydroxydopamine treatment.
Further work is needed to ﬁnally provide deﬁnitive evidence
as to whether peripherally or centrally generated steroids are the
primemediators in regulating glial activity.Of note, several aspects
of the neuroprotective actions of estrogens are achieved only
with doses of estradiol that have been termed “pharmacological”
because they exceed the normal circulating levels in females and,
certainly, in males. These include estrogen’s ability to promote
non-inﬂammatory phagocytosis of apoptotic neuron-like cells
(see above, Figure 4 and McArthur, Vohra, Solito and Gillies,
unpublished observations) as well as its anti-oxidant and anti-
neuroinﬂammatory actions (Green and Simpkins, 2000; Liu et al.,
2005; Nilsen, 2008). However, our recent knowledge that brain
injury may induce an increase both in the central production
of estrogens, as well as glial sensitivity to estrogens, highlights
the likelihood that circulating “physiological” levels may well be
exceeded in the brain where much higher levels may be achieved
(Mukai et al., 2006). Thus it is tempting to speculate that local
production of estrogens via glial aromatase may represent the
principalmodewhereby estrogen exerts its neuroprotective effects,
probably through regulation of the pro- and anti-inﬂammatory
balance of astrocytic and microglial reactivity, with only a limited
contribution from gonadal hormones. Our evidence that central
administration of an aromatase inhibitor can exacerbate striatal
damage in experimental PD would support this view (see Impact
of Centrally Generated Sex Steroids in Experimental PD, Figure 3;
McArthur et al., 2007). However, other studies suggest that a
gonadal source of estrogens in females is important for regulating
microglial reactivity in animal models of inﬂammation (Vegeto
et al., 2006). Equally, a gonadal source of an estrogen precursor
(testosterone) in males, which is subsequently aromatized in the
brain, appears to be important for neuroprotection against exci-
totoxic injury (Azcoitia et al., 2001). It therefore remains an open
question as to the relative importance of centrally and peripherally
generated estrogens.
CONCLUDING REMARKS
Parkinson’s disease is already one of the most prevalent neurode-
generative disorders, second only to Alzheimer’s disease, and its
incidence and prevalence are expected to rise markedly in the
near future (Pavon et al., 2010). However, despite many decades
of research, options to prevent or delay disease onset and/or
progression are unmet therapeutic needs, and dopamine replace-
ment therapies to alleviate motor symptoms have remained the
principal therapeutic option for almost half a century (Meiss-
ner et al., 2011). A wealth of evidence now documents notable
sex differences in the epidemiology, clinical features, molecular
pathology, and treatment outcomes in PD, with women being
relatively protected from, and having a more benign pre-clinical
phase of the disease compared with men (Haaxma et al., 2007;
Pavon et al., 2010). Knowledge of factors underlying sex differ-
ences in the pathophysiology of PD will therefore offer consid-
erable insight into improving diagnosis and treatments, which
need to be tailored to the speciﬁc needs of men and women.
In this review we have focused on the precise contributions of
sex steroid hormones, and estrogens in particular. Much attention
has focused on the ostensibly neuroprotective effects of estrogen
in experimental models of PD, but the term “neuroprotection”
has been used broadly and often describes a relative sparing of
striatal dopamine rather than a deﬁned limitation of neuronal
death. Therefore, we have developed the view that any protec-
tive capacity offered by endogenous sex steroid hormones in PD
centers on their ability to promote adaptive compensatory mech-
anisms in the partially injured neuronal network, with potential
to inﬂuence onset or progression of disease. However, inherent
sexual dimorphisms in the NSDA-related circuitry, which may
themselves be largely attributable to the sex-differentiating inﬂu-
ences of gonadal steroids during development, represent biological
factors that will also affect male/female differences in vulnera-
bility to CNS disorders and responses to sex hormones (Gillies
and McArthur, 2010a). Together, these factors account for sex-
speciﬁc responses to peripheral sex hormones in experimental
PD, which are protective in females, but not in males. Impor-
tantly, however, it appears that aromatase activity local to the
damagedNSDAhas amore restricted effect on the neural network,
allowing centrally generated estrogen to protect against striatal
dopamine loss in males as well as females. These observations
leave us with two challenging questions which urgently need to be
answered: precisely what is the nature of the sexually dimorphic
neural circuitry which underlies sex differences in responsive-
ness of the healthy and injured NSDA system, and what are the
relative contributions of estrogens/estrogen precursors derived
from the gonads and neural cells (especially astrocytes)? Although
in its infancy, a better understanding of such “neuroendocrine”
mechanisms in the NSDA offers considerable potential for the
development of novel, sex-speciﬁc, hormone-based treatments
in PD.
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